Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EGFR Exon 20–Altered NSCLC: A Personalized Approach to Improve Patient Outcomes
  • CME

Credits Available
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: December 28, 2021 Expiration: December 27, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Pharmaceutica NV
Enriqueta Felip, MD
Alexander Spira, MD, PhD, FACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC, including the use of tissue-based and blood-based biomarker testing for evaluation of EGFR exon 20 mutation status
  • Describe the medical need for new therapies for patients with NSCLC harboring EGFR exon 20 insertion mutations or MET amplifications
  • Appraise the available and emerging clinical trial data on EGFR-MET bispecific antibody and next-generation EGFR TKI therapies in the management of patients with advanced NSCLC with EGFR exon 20 insertion mutations
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for NSCLC with EGFR exon 20 mutations

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d'Hebron University Hospital
Barcelona, Spain

Enriqueta Felip, MD, has disclosed that she has received funds for research support from Fundación Merck Salud; consulting fees from AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, Novartis, Pfizer, Roche, Samsung, and Takeda; fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda; and other financial or material support from Grífols.
Alexander Spira, MD, PhD, FACP

Director, NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director, Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Alexander Spira, MD, PhD, FACP, has disclosed that he has received funds for research support from AbbVie, ADCT, Amgen, Arch Therapeutics, Astellas, Astex Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Ignyta, Incyte, Janssen, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Mirati Therapeutics, Newlink Genetics, Novartis, Plexxikon, Roche, Rubius, Takeda, and Trovagene and consulting fees from Amgen, Array Biopharma, AstraZeneca, Bristol-Myers Squibb, Gritstone, Incyte, Janssen, Jazz Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Novartis, and Takeda.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncologists, pathologists, pulmonologists, and other healthcare professionals who care for patients with NSCLC.

Goal

The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to plan individualized treatment for patients with EGFR Mut+ NSCLC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 28, 2021, through December 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

EGFR Exon 20–Altered NSCLC: A Personalized Approach to Improve Patient Outcomes
  • CME

Loading...
Watch this on-demand webcast capturing a live CCO webinar of global experts discussing the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC.
Enriqueta Felip, MD
Alexander Spira, MD, PhD, FACP
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Released: December 28, 2021 Expiration: December 27, 2022

Related Content

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in biomarker testing for optimal management of advanced NSCLC

Zofia Piotrowska, MD, MHS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 27, 2022 Expired: May 26, 2023

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Pharmaceutica NV

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings